AICAR is a small-molecule nucleoside analogue—it is not a peptide, has no amino-acid sequence, and should not be described using peptide-specific parameters such as peptide purity, peptide content, or peptide reconstitution protocols.
The information below is limited to in-vitro experiments and institutionally approved laboratory animal-model research. It is not a guide for human use, veterinary treatment, personal use or performance enhancement.

Any concentrations or preparation methods mentioned in this article are laboratory references only and must not be converted into human or veterinary doses.
The name “AICAR” can refer to two related but different compounds. In pharmacological and cell-culture contexts, “AICAR” commonly refers to AICA riboside (acadesine), the nucleoside analogue normally added to cell cultures.
In purine-biosynthesis literature, AICAR may refer to the phosphorylated ribonucleotide ZMP (AICA ribotide). Throughout this article, the two forms are referred to by their distinct chemical names to avoid confusion in weighing, molarity calculations, and experimental interpretation.
The material normally added to cell cultures is AICA riboside. It is a nucleoside analogue, not a peptide.
After it enters cells via adenosine transporters, it can be phosphorylated by adenosine kinase into ZMP, which can affect AMPK and several other metabolic pathways.
Because AICAR has effects outside AMPK, it should not be treated as a fully selective AMPK research tool.
What AICAR Is
| Property | AICA Riboside / Acadesine | ZMP / AICA Ribotide |
|---|---|---|
| Common names | AICA riboside, acadesine | ZMP, AICAR monophosphate, AICA ribotide |
| Compound type | Nucleoside analogue (small molecule) | Ribonucleotide and purine-pathway intermediate |
| Peptide status | Not a peptide—no amino-acid sequence, no peptide-bond pattern, no peptide-related parameters apply | Not a peptide—no amino-acid sequence, no peptide-bond pattern, no peptide-related parameters apply |
| CAS number | 2627-69-2 | 3031-94-5 (parent compound); salt, ionic, or hydrated forms may carry different CAS numbers |
| Molecular formula | C9H14N4O5 | C9H15N4O8P |
| Average molecular weight | 258.23 g/mol (monoisotopic exact mass 258.0964 Da) | 338.21 g/mol |
| PubChem CID | 17513 | 65110 |
| Additional identifiers | UNII 53IEF47846; EC 220-097-5; ChEBI 28498; DrugBank DB04944; KEGG D02742 | — |
| Computed properties (acadesine) | XLogP3-AA −2.2; TPSA 157 Ų; HBD 5; HBA 7; melting point 213 °C (decomposition); protein binding ~1%; Phase 3 (highest clinical trial phase) | |
The chemical identity, molecular formula, molecular weight and CAS number of acadesine are listed in the PubChem compound record (CID 17513).[1]
The molecular formula of neutral AICA ribotide is C9H15N4O8P, and its molecular weight is approximately 338.21 g/mol (PubChem CID 65110).
For laboratory weighing and molarity calculations, researchers must confirm whether the material is AICA riboside or ZMP, and whether it is supplied as the free base, a salt, a hydrate, or another chemical form, using the lot-specific COA.[2]
How AICAR Works in Laboratory Studies
After AICA riboside is taken up by cells, adenosine kinase can add a phosphate group and form ZMP.
Early rat skeletal-muscle experiments by Merrill et al. (1997) linked ZMP formation with increased AMPK activity, ACC phosphorylation, fatty-acid oxidation and glucose-uptake measurements.[3]
The foundational work by Corton et al. (1995) demonstrated that ZMP can mimic some of the allosteric effects of AMP on AMPK—including promotion of upstream kinase-mediated phosphorylation of the α subunit at Thr172 and inhibition of dephosphorylation—providing the mechanistic framework for understanding AICAR as a research tool.
These processes work together rather than through one simple on-or-off step. AMPK is a heterotrimeric enzyme composed of α (catalytic), β (scaffold), and γ (regulatory) subunits.[4]
ZMP is not an irreversible metabolic dead end. It is also a normal intermediate in de-novo purine synthesis.
The enzyme ATIC can convert ZMP and 10-formyltetrahydrofolate into FAICAR, which is then used to form inosine monophosphate (IMP).
The amount of ZMP that builds up in a cell therefore depends on uptake, phosphorylation and downstream metabolism—ZMP accumulation is not directly proportional to the extracellular AICA riboside concentration in a simple linear manner.[5]
For this reason, AICAR does more than activate AMPK. It may also change purine metabolism and affect other AMP-sensitive enzymes.
An observed effect after AICAR treatment should not automatically be described as an AMPK-dependent effect.
Common Research Readouts
Researchers commonly measure several markers together instead of relying on one result.
- Phospho-AMPK Thr172 and total AMPK: These measurements show whether AMPK phosphorylation changed, but they do not prove that every later effect was caused by AMPK.
- Phospho-ACC and total ACC: ACC is a common downstream AMPK marker. The reported phosphorylation site must match the species, protein isoform and antibody used.
- Glucose-uptake and fatty-acid oxidation assays: Changes have been reported in isolated rat epitrochlearis muscle, but the results remain specific to the experimental model and conditions—the 1997 Merrill study used this specific muscle preparation.[3]
- PGC-1α-related markers: Laboratory skeletal-muscle research has shown that AMPK can directly phosphorylate PGC-1α and affect some of its gene-regulating functions.[6]
- Raptor and mTORC1-related markers: Cell studies have shown that AMPK can phosphorylate Raptor at Ser792 and reduce mTORC1 signalling under the tested conditions.[7]
- Cell viability: Viability or membrane-integrity testing should be performed at the same concentration and exposure time as the main experiment.
A single Western blot band is not enough to prove a complete biological mechanism. Results are stronger when pathway markers, functional assays and genetic controls point in the same direction.
Why AICAR Alone Does Not Prove AMPK Dependence
AICAR can produce AMPK-independent effects. In the tested T-cell models, some AICAR responses remained when normal AMPK activity was absent, supporting the possibility of AMPK-independent effects that should be evaluated in each experimental system.[8]
Where possible, an AICAR study should include one or more of the following controls:
- AMPK alpha-1 and alpha-2 knockout or knockdown cells;
- A kinase-inactive AMPK construct;
- A rescue experiment that restores AMPK expression;
- A structurally different AMPK activator;
- Direct measurement of intracellular ZMP or related purine metabolites;
- A concentration-response and time-course experiment;
- Viability controls at every important concentration.
A structurally different AMPK activator can provide useful supporting evidence, but it does not replace a genetic control. Different activators can have their own off-target effects or work differently with different AMPK subunit combinations.
Compound C Is Not a Selective AMPK Control
Compound C, also called dorsomorphin, is often described as an AMPK inhibitor. However, it affects other kinases and can change cell behaviour through AMPK-independent mechanisms.
In one cell study, its anti-proliferative effects remained when AMPK was absent.[9]
Compound C may be included as a supporting pharmacological control, but it should not be the only evidence used to claim that an AICAR effect depends on AMPK.
Use of Etomoxir in Fatty-Acid Oxidation Studies
Etomoxir is sometimes used when researchers study CPT1 and fatty-acid oxidation. Its concentration and treatment time must be chosen carefully.
High concentrations can cause effects that are not caused by CPT1 inhibition.
One study found that etomoxir could disrupt coenzyme-A balance when used at concentrations higher than those needed to inhibit CPT1.[10]
Another study found that 200 µM etomoxir directly inhibited mitochondrial respiratory complex I in the tested cancer-cell models.[11]
A fixed concentration such as 40 µM should therefore not be presented as a universal CPT1 control.
Researchers should use the lowest concentration validated for their model and, where possible, confirm the result with CPT1A or CPT1B genetic testing.
Key Mouse Study
In a 2008 study by Narkar et al., sedentary male C57BL/6J mice received AICAR (500 mg/kg/day intraperitoneally) during a four-week laboratory experiment.
The researchers reported an approximately 44% increase in treadmill running distance in that specific mouse model and described AICAR as an “exercise mimetic” in the context of the PPARδ/AMPK pathway interactions investigated.[12]
This finding must remain clearly labelled as a laboratory mouse result obtained under a specific dosing protocol (500 mg/kg/day i.p. for 4 weeks in male C57BL/6J mice).
It does not prove the same effect in humans and does not provide a safe human dose, a fitness recommendation or a performance-enhancement guide.
Anti-Doping Status
AICAR is included in the World Anti-Doping Agency 2026 Prohibited List under the category of metabolic modulators (section S4.4, “AMPK activators”) and is prohibited at all times in sport (both in-competition and out-of-competition).[13]
This article does not provide advice on athletic use, human administration or methods intended to avoid anti-doping controls.
Laboratory Concentration and Study Design
There is no single AICAR concentration that is suitable for every cell line or experiment. The result can change with the cell type, culture medium, exposure time, cell density and measured endpoint.
A basic in-vitro study should normally include:
- An untreated or vehicle control;
- Several AICAR concentrations rather than one concentration;
- More than one treatment time where practical;
- AMPK and downstream pathway measurements;
- Cell-viability testing;
- A genetic or independent pathway control;
- Enough biological replicates for the planned analysis.
Published concentrations should be treated as starting references, not universal instructions. Each laboratory must validate the range for its own model.
Laboratory Handling and Solution Preparation
Laboratory Use Only: The information in this section is for professional laboratory solution preparation. It must not be used to prepare a product for injection, consumption, veterinary administration or personal use.
- Confirm whether the vial contains AICA riboside, ZMP, a salt or another derivative. AICAR is a small-molecule nucleoside, not a peptide—peptide-specific parameters such as peptide purity, peptide content, amino-acid analysis, or TFA/acetate counterion content (in the peptide-specific sense) do not apply.
- Use the molecular weight listed on the vial and lot-specific COA—258.23 g/mol for acadesine free base; different values for salts or hydrates.
- Follow the storage temperature stated on the product label or COA.
- Do not assign a universal shelf life to the powder or solution without stability data.
- Do not assume that water and PBS give the same solubility.
- Do not prepare a stock above the verified solubility of the specific batch.
- Check for particles or precipitation after preparation and after dilution into culture medium.
- Use single-use aliquots where frozen solution storage has been validated.
- Avoid repeated freeze-thaw cycles unless the solution has been shown to remain stable.
For AICA riboside with a molecular weight of 258.23 g/mol, the mass for an in-vitro stock can be calculated with the following formula:
Mass (mg) = molecular weight (g/mol) × concentration (mM) × volume (mL) ÷ 1000
For later dilution, the usual laboratory equation is:
C1V1 = C2V2
These equations only calculate laboratory solution concentrations. They do not show that a concentration is soluble, stable or suitable for a particular experiment.
Passing a solution through a laboratory filter does not prove pharmaceutical sterility, low endotoxin content or suitability for human or veterinary administration.
How to Read an AICAR COA
A COA should be linked to a specific lot number. It should not be accepted only because it shows a high HPLC purity value.
For AICAR, which is a small-molecule nucleoside and not a peptide, COA review should focus on chemical identity, chromatographic purity (HPLC or UPLC), assay/content, water or loss on drying, residual solvents, and counterion or salt form where applicable—rather than peptide-specific parameters such as peptide content or amino-acid analysis.
General analytical guidance treats identity, assay, impurities and other quality tests as separate parts of a specification. ICH Q6A and Q2(R2) are regulatory guidelines for pharmaceutical drug substances and products.
They are cited here only as general analytical-quality references and do not automatically establish mandatory release specifications for an RUO research reagent.[14]
| COA Item | What It Means | What to Check |
|---|---|---|
| Product and batch details | Links the test results to a specific material | Product name, lot number, chemical form, formula and molecular weight |
| Identity | Checks whether the expected compound is present | Mass spectrometry, NMR, infrared data or another suitable identity method. For HPLC, retention time alone is generally not sufficient. |
| HPLC purity | Shows relative chromatographic peak area under the stated method | Method, detector wavelength, main-peak result and impurity limits. HPLC area purity is not the same as weight-based assay content. |
| Assay or content | Estimates how much target compound is present by weight | Whether the result is reported as-is, dried, anhydrous or solvent-free; water, salts, and residual solvents may not be proportionally reflected in HPLC area purity |
| Water or loss on drying | Checks water or volatile material | Test method (e.g., Karl Fischer) and whether the value affects molarity calculations |
| Residual solvents | Checks solvents left from manufacturing | Method, listed solvents and acceptance limits |
| Storage and retest information | States the tested storage condition or review period | Temperature, light or moisture limits and any retest date |
HPLC area purity is not the same as weight-based assay.
Water, salts, residual solvents and compounds that are not detected well by the HPLC method may not be fully represented by the main-peak percentage.
Identity should be supported by a suitable method or a combination of methods, such as HPLC retention time together with mass spectrometry, NMR, or another orthogonal technique.[14]
The analytical method must also be suitable for its intended purpose. Depending on the test, this may require checks of selectivity, accuracy, precision, range, detection capability and robustness.
ICH Q2(R2) describes these validation characteristics for regulated analytical procedures; not every characteristic is required for every type of test (e.g., identity tests primarily require specificity, whereas quantitative assays require specificity, accuracy, precision, and range).[15]
What a COA Does Not Prove
A COA reports selected quality-control results for one batch. It does not prove:
- Safety for human use;
- Safety for veterinary use;
- Suitability for injection, consumption or cosmetic use;
- Sterility or endotoxin status unless those tests are specifically listed;
- Biological activity in every cell line or assay;
- That an observed effect is caused by AMPK;
- That a result from a cell or mouse study applies to humans.
How Results Should Be Reported
Every experiment should report the exact compound, supplier, catalogue number, batch number, solvent, final concentration, treatment time, biological model and measured endpoint.
Clear wording includes:
- “In the tested in-vitro cell model, AICAR treatment was associated with…”
- “In the isolated rat epitrochlearis muscle experiment, the researchers observed…”
- “In the cited laboratory mouse model (male C57BL/6J, 500 mg/kg/day i.p. for 4 weeks), the study reported…”
- “The result supports an AMPK-related mechanism but does not rule out AMPK-independent effects.”
Avoid broad statements such as “AICAR improves metabolism,” “AICAR burns fat,” “AICAR lowers glucose” or “AICAR replaces exercise.” These statements remove the experimental limits and can be misunderstood as human-use claims.
Summary
AICAR usually refers to AICA riboside (acadesine), a small-molecule nucleoside research reagent (not a peptide) that cells can convert into ZMP. ZMP can affect AMPK by mimicking some allosteric effects of AMP—promoting Thr172 phosphorylation and inhibiting dephosphorylation—but it also takes part in purine metabolism and can produce AMPK-independent effects, as demonstrated in specific T-cell models.
A reliable AICAR experiment should use more than one pathway marker, include viability testing and use genetic or independent controls where possible.
Product handling and concentration calculations must be based on the exact chemical form and lot-specific documents.
A high HPLC purity result alone does not prove identity, assay value, sterility, biological specificity or safety for human use.
Research Use Only Disclaimer
Research Use Only: The AICAR product described on this page is supplied for laboratory research purposes only and is not approved for human use.
This article provides informational context regarding published preclinical laboratory research and general analytical-quality considerations. It does not constitute medical, clinical, veterinary guidance or treatment advice.
A lot-specific certificate of analysis documents selected laboratory raw-material quality-control attributes only. HPLC purity, mass confirmation, assay data or other release information do not demonstrate human or veterinary safety, sterility, endotoxin suitability, clinical efficacy or suitability for administration.